Pronova BioPharma ASA

Pronova BioPharma ASA (OSL:PRON) 23 October, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) will publish the group's third quarter results on Tuesday 4 November 2008.

Pronova BioPharma ASA (OSL:PRON) 16 September 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) will give a presentation at the UBS Global Life Sciences Conference in New York 23 September. The presentation will be available as webcast.

Pronova BioPharma ASA (OSL:PRON) 31 August, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") announces that the Phase III outcome trial GISSI-Heart Failure demonstrated that Omacor® reduced mortality and morbidity in patients with congestive heart failure (CHF).Both primary endpoints were met in the 7000 patient trial. The results were presented today at the European Society of Cardiology (ESC) Hot Line session in Munich, Germany. The findings were also published in The Lancet.

Pronova BioPharma ASA (OSL:PRON) 25 August, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) will host a webcast on Monday 1 September where top-line data from the GISSI-HF study will be presented.

Pronova BioPharma ASA (OSL:PRON) 22 August, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") today announces that it has entered into a sourcing agreement with an undisclosed third party manufacturer for the supply of intermediaries for the manufacture of Active Pharmaceutical Ingredients (APIs). The sourcing agreement will enable increased manufactured volumes of APIs in excess of earlier communicated volumes for 2009.

Pronova BioPharma ASA (OSL:PRON) 19 August, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or the "company") announces that the District Court of Rome, Italy, has decided not to uphold Pronova BioPharma's motion for a preliminary injunction against Chiesi Farmaceutici SpA ("Chiesi Farmaceutici"). Written arguments of the court's ruling have not yet been made available, and consequently the company is not in a position to comment on the contents of the ruling. The company believes the ruling will have no commercial impact given the continued strong growth in end-user sales and excess demand for the Active Pharmaceutical Ingredient on a global basis.

Pronova BioPharma ASA Pronova BioPharma ASA reports record-high second quarter results, with 34.3 per cent revenue growth and 23.5 per cent EBITDA growth. Global end-user sales were up 55 per cent to USD 283.3 million (May YTD), driven by market share growth in the USA. The blockbuster potential of the company's product is highlighted by a global run-rate in May 2008 of some USD 735 million (USD 475 million in May 2007).

Pronova BioPharma ASA 29 July, 2008, Lysaker, Norway: Pronova BioPharma ASA (OSE: PRON.OL) will publish the group's second quarter results on Tuesday 5 August 2008.

Pronova BioPharma ASA Please find enclosed the presentation of Pronova BioPharma ASA to be held on 28 May at the 13th Annual Carnegie Nordic Health Care Seminar in Stockholm, and on 29 May at the UBS Global Specialty Pharmaceutical and Generics Conference in London.